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sula et al., 1996; Wang et al., 1996), but not caspase-1Martha A. Alexander-Miller,† Jay A. Berzofsky,†
or caspase-6 (Darmon et al., 1994; Srinivasula et al.,Charles M. Zacharchuk,‡ and Pierre A. Henkart*
1996). Such granzyme B–mediated caspase activation*Experimental Immunology Branch
can give rise to cell-free apoptoticnuclear damage (Mar-†Metabolism Branch
tin et al., 1996). Other studies have elucidated a molecu-‡Laboratory of Immune Cell Biology
lar pathway leading from Fas cross-linking to activationNational Cancer Institute
of caspase-8 (FLICE/MACH) via the linker moleculeNational Institutes of Health
FADD/MORT1 (Muzio et al., 1996; Boldin et al., 1996).Bethesda, Maryland 20892
Together, these results suggest that the activation of
caspases is a common downstream element in both
CTL death pathways.Summary
While the above findings support a common func-
tional role for caspases, other recent data are lessActivation of ICE/Ced-3 family proteases (caspases)
readily explained by this model. CTL from granzyme Bhas been proposed to mediate both the granule exo-
knockout mice show largely normal target lysis, whilecytosis and Fas–Fas ligand pathways of rapid target
apoptotic nuclear damage is modestly impaired (Heuselcell death by cytotoxic T lymphocytes. In agreement
et al., 1994; Darmon et al., 1996; Shresta et al., 1995).with this model, two peptide fluoromethyl ketone cas-
Furthermore, the relationship between CTL-induced tar-pase inhibitors and baculovirus p35 blocked apoptotic
get apoptotic nuclear damage and target lysis is unclear.nuclear damage and target cell lysis by the CTL-medi-
While most CTL target cells die with apoptotic features,ated Fas–Fas ligand pathway. The peptide caspase
this is not always the case (Nishioka and Welsh, 1992;inhibitors also blocked drug-induced apoptotic cell
Sellins and Cohen, 1991). Neither of the two death path-death in tumor cells. In contrast, the caspase inhibitors
ways used by CTL requires target nuclei (Nakajima etblocked CTL granule exocytosis–induced target apop-
al., 1995a), and thus caspase-induced nuclear damagetotic nuclear damage, but did not inhibit target lysis.
is not necessary for cell death as measured by nonnu-These results are consistent with recent demonstra-
clear criteria. The sequence of molecular steps leadingtions that granzyme B can activate caspases leading
from caspase activation to nonnuclear criteria of cellto apoptotic nuclear damage, but show that target cell
death remains undefined in any system, and in this studylysis by CTL granule exocytosis occurs by a caspase-
we have tested whether caspases are involved in CTL-
independent pathway.
induced target cell death.
One class of caspase inhibitor used in these experi-
Introduction ments is the peptide-based fluoromethyl ketones, which
are potent, irreversible inhibitors of cysteine proteases
Cytotoxic T lymphocytes (CTL) rapidly kill target cells in (Sarin et al., 1996; Shaw, 1990). These inhibitors, con-
vitro using two effector pathways: a secretory pathway taining aspartic acid at the P1 site, are selective for
involving exocytosis of preformed granules and the Fas caspases and do not block the aspartic acid–selective
ligand (FasL)–Fas pathway, in which surface FasL on serine protease granzyme B (Sarin et al., 1996). They
CTL cross-links Fas on target cells (Henkart, 1994). As are membrane permeableand nontoxic to cellsand have
both pathways can induce apoptotic changes in target been shown to block varied apoptotic death processes
nuclei, it has been generally assumed that they share in intact cells, as shown in assays of both nuclear dam-
downstream biochemical events common to apoptotic age and cell lysis (Sarin et al., 1996; Jacobson et al.,
death. Experiments with inhibitors of caspases (Alnemri 1996; Pronk et al., 1996; Fearnhead et al., 1995). The
et al., 1996) (interleukin-1b-converting enzyme [ICE] other type of caspase inhibitor used is the baculovirus
family proteases) strongly implicate this enzyme family protein p35 (Clem et al., 1991), which has been shown
as a common mediator of apoptotic cell death (Henkart, to inhibit caspase-1 through caspase-4 but not gran-
1996), and it is an appealing hypothesis that caspase zyme B (Xue and Horvitz, 1995; Bump et al., 1995). This
activation is a common element in target cell death by protein inhibitor can be introduced into cells via trans-
both the granule exocytosis and Fas pathways. fection or injection and has been shown to block various
In support of this hypothesis, recent studies have pro- examples of apoptotic cell death (Henkart, 1996).
vided direct molecular evidence for caspase activation The results of this study show that caspases are not
in both of these pathways. The CTL granule-derived required for target cell death via the CTL granule exo-
serine protease granzyme B has an unusual proteolytic cytosis pathway. Target cell lysis via the granule exo-
specificity requiring aspartic acid in the P1 position, cytosis pathway is not blocked by either class of cas-
which is also the specificity required for caspase pro- pase inhibitor, yet they block CTL-induced lysis by the
cessing leading to activation. Accordingly, granzyme B FasL–Fas death pathway. However, caspase inhibitors
has been shown by several laboratories to process and do effectively block nuclear damage induced by both
activate many of the known caspases (Darmon et al., pathways. These results suggest that, while the gran-
1995, 1996; Chinnaiyan et al., 1996; Duan et al., 1996; zyme-activated caspases lead to apoptotic nuclear
damage, caspases are not involved in target cell deathFernandes-Alnemri et al., 1996; Gu et al., 1996; Martin
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Figure 1. Effect of Peptide-FMK Caspase In-
hibitors on CTL-Mediated Killing of Thymo-
cytes
Thymocytes from B10 (solid lines) or lpr (bro-
ken lines) mice were tested as targets for cy-
totoxicity by allogeneic CTL (A and B) or
FasL-bearing d11S CTL (C and D) in the pres-
ence of peptide-FMKs in a 4 hr chromium
release assay. ZVAD-FMK, squares; BD-
FMK, circles; ZFA-FMK, diamonds. In (A) and
(B), when B10 thymocytes were used as tar-
gets, soluble anti-Fas IgG (10 mg/ml) was
added to the wells. Target lysis was mea-
sured by 51Cr release (A and C), and nuclear
morphology of targets marked with di-I-C16
was assessed with Hoechst 33342 (B and D).
In (A) and (C), error bars show the mean 6
SEM from three individual wells.
by the granule exocytosis pathway as they are in the other triggers of apoptotic death in thymocytes (Sarin
et al., 1996). The most striking finding was their inabilityFas pathway.
to inhibit thymocyte lysis in Figure 1A.
Results
Peptide Caspase Inhibitors Block Tumor
Cell Lysis Induced by Various AgentsPeptide Caspase Inhibitors Block CTL-Induced
Thymocyte Lysis via Fas but Not but Not CTL Granule Exocytosis
Since cytotoxicity experiments with CTL typically mea-Granule Exocytosis
Previous studies in our laboratory showed that two pep- sure the lysis of tumor targetswith the 51Cr release assay,
we tested the ability of the fluoromethyl ketone caspasetide inhibitors of caspases, BD-FMK (Boc-Asp(OMe)-
fluoromethyl ketone) and ZVAD-FMK (Cbz-Val-Ala-Asp inhibitors to block lysis induced by several agents capa-
ble of inducing apoptotic death in tumor cells. Signifi-(OMe)-fluoromethyl ketone), specifically blocked apop-
totic cell death in thymocytes, peripheral T cell blasts, cant lysis was not observed before 14 hr with these
agents. The DNA topoisomerase I inhibitor campto-and T cell lines (Sarin et al., 1996). In thymocytes, these
two reagents were equally potent and completely thecin, the protein phosphatase inhibitor staurosporine,
and the alkylating chemotherapeutic drug cisplatin, atblocked both apoptotic nuclear damage and cell lysis
after 16 hr triggered by four independent input path- the concentrations used in Figure 2, were found to in-
duce apoptotic nuclear damage in greater than 50% ofways: corticosteroid, DNA damage by irradiation or eto-
poside, immobilized anti-Fas, and immobilized anti- Jurkat and L1210 cells by 18 hr, and this was blocked
specifically by both ZVAD-FMK and BD-FMK (data notCD3. It was thus of interest to compare the ability of
these caspase inhibitors to block CTL-induced death of shown). Figure 2 shows that peptide-FMK caspase in-
hibitors inhibited lysis of both Jurkat and L1210 tumorsthymocytes by the granule exocytosis and FasL–Fas
pathways (Figure 1). To examine the granule exocytosis induced by these agents. Unlike thymocytes, BD-FMK
and ZVAD-FMK showed different relative potencies inpathway selectively, we incubated B10thymocyte target
cells with immunoglobulin G (IgG) anti-Fas or used lpr blocking such tumor death, correlating with the cell type
rather than the stimulus (Sarin et al., 1996),thymocytes. Apoptotic nuclear morphology induced at
4 hr by the CTL granule exocytosis pathway (Figure 1B) The ability of peptide caspase inhibitors to block CTL
killing of these tumor targets was also examined (Figurewas specifically blocked by BD-FMK and ZVAD-FMK,
with no effect of the control inhibitor ZFA-FMK (Cbz- 3) by measuring lysis and CTL-induced apoptotic nu-
clear damage assessed by fluorescence microscopy orPhe-Ala-fluoromethyl ketone). In contrast with the
blocking of CTL-induced apoptotic morphology by cas- DNA release after 4 hr. In Jurkat cells, caspase inhibitors
effectively blocked the rapid CTL-induced lysis of cellspase inhibitors, lysis of thymocytes was not blocked
(Figure 1A). Figures 1C and 1D show the effects of these via the FasL–Fas pathway induced by d11S CTL (Figures
3C and 3D). In contrast, when traditional allo-CTL werecaspase inhibitors on killing via the CTL-triggered FasL–
Fas pathway in the same assay, using the FasL-bearing used with the Fas pathway blocked by IgG anti-Fas,
these caspase inhibitors blockedapoptotic nuclearmor-CTL hybridoma d11S (Rouvier et al., 1993). Caspase
inhibitors specifically and completely blocked both tar- phology but not the lysis of these target cells (Figures
3A and 3B). Similar experiments were performed usingget lysis and apoptotic nuclear morphology, consistent
with recent reports showing a role for caspases in Fas- Fasneg murine leukemia L1210 target cells to test the
granule exocytosis pathway and a Faspos L1210 transfec-triggered death (Muzio et al., 1996; Na et al., 1996).
ZVAD-FMK and BD-FMK wereequally potent in blocking tant to examine the Fas–FasL pathway with d11S ef-
fectors (Figures 3E–3H). For these experiments, apop-apoptotic nuclear damage and Fas-mediated lysis of
thymocyte targets, similar to the results obtained with totic nuclear damage was measured by target DNA
Caspase-Independent Target Lysis by CTL
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Figure 2. Peptide-FMK Caspase Inhibitors
Blocking Tumor Lysis by Agents Inducing
Apoptotic Death
51Cr-labeled Jurkat (A–C) or L1210 (D and E)
tumor cells were incubated for 18 hr with 10
mM camptothecin (A and D), 50 nM stauro-
sporine (B and E), or 25 nM cisplatin (C),
and lysis was measured at the indicated con-
centrations of peptide-FMKs. ZVAD-FMK,
squares; BD-FMK, circles; ZFA-FMK, dia-
monds. Data shown are mean of triplicates
with SEM.
release. As observed with Jurkat targets, the caspase and lysis of the transfected cells was measured using
cotransfected b-galactosidase as a marker (Memon etinhibitors blocked apoptotic nuclear damage by both
pathways (Figures 3F and 3H), and effectively blocked al., 1995). In L1210-Fas cells (Figure 5D), expression of
p35 dramatically reduced CTL-induced lysis by the FasFasL–Fas-mediated lysis (Figure 3G), but failed to inhibit
lysis induced by the granule exocytosis pathway (Figure pathway. However, when Fasneg L1210 cells were used
as targets for the CTL granule exocytosis pathway, lysis3E). It is interesting to note that the two peptide caspase
inhibitors showed approximately equal potency in was not affected by p35 expression (Figure 5A). In con-
trast, apoptotic nuclear damage via granule exocytosisblocking CTL-induced damage, in contrast with their
inhibition of lysis induced by other agents (Figure 2). as assessed by both nuclear morphology and DNA re-
lease was effectively inhibited by p35 expression (Fig-Overall, the results with CTL and the tumor target cells
were essentially the same as with thymocyte targets. ures 5B and 5C). Parallel experiments with p35 expres-
sion in Jurkat target cells yielded similar results, in that
p35 expression inhibited Fas-mediated lysis but not theEffect of Peptide Caspase Inhibitors on Cell
granule exocytosis pathway (data not shown).Death Induced by Internalized Trypsin
One possible interpretation of the above results is that
the lysis of these targets via granule exocytosis is due Discussion
solely to perforin/cytolysin, while the apoptotic nuclear
damage is due to granzymes acting via caspases. Al- Taken together, these results show that target cell lysis
though previous experiments with RBL transfectants induced by CTL via granule exocytosis is independent
argue that granzymes are necessary for efficient target of caspases, even though apoptotic nuclear damage
lysis (Nakajima et al., 1995c; Nakajima and Henkart, induced by this pathway requires the activation of these
1994), we tested the ability of caspase inhibitors to block proteases. Several important controls add considerably
apoptotic death induced by a purely proteolytic trigger. to the strength of these conclusions. Lysis of both thy-
When tumor cell death was induced within 90 min by mocytes and tumor targets by other agents inducing
cytoplasmic loading of trypsin via osmotic lysis of pino- apoptotic death was blocked by the peptide-FMK cas-
somes (Williams and Henkart, 1994), both peptide cas- pase inhibitors (Sarin et al., 1996; Figure 2), although
pase inhibitors blocked apoptotic nuclear morphology lysis requires 12–16 hr rather than the 2–4 hr seen with
(Figure 4B), but did not detectably inhibit target lysis as CTL. In addition, target lysis by the CTL-induced FasL–
judged by trypan blue (Figure 4A). Thus, the death of Fas pathway in the 4 hr assay is blocked completely by
these target cells triggered by internal tryptic proteolysis both types of caspase inhibitors using the same target
behaves similarly to death induced by CTL granule exo- cells in experiments where the CTL granule exocytosis–
cytosis, with caspase inhibitors able to block nuclear induced lysis was not blocked. Thus, under the experi-
damage but not lysis. mental conditions used, lysis of the target cells was not
inherently resistant to the caspase inhibitors. Further-
more, the inhibition of target nuclear damage by theBaculovirus p35 Blocks CTL-Induced Lysis
via Fas but Not Granule Exocytosis granule exocytosis pathway shows that these inhibitors
are active in the target cells during the cytotoxic pro-Although ZVAD-FMK and BD-FMK have been shown to
block some caspases (Sarin et al., 1996), it is possible cess, making it unlikely that target lysis via the granule
exocytosis pathway involves caspases resistant to thethat they fail to block other members of this family. We
thus sought to confirm the results with peptide caspase inhibitors used.
The specificity of caspase inhibitors used in theseinhibitors using the baculovirus protein p35, a potent
general blocker of caspases (Bump et al., 1995). p35 was studies is critical to the conclusions drawn. The peptide-
FMK inhibitors used appear to be specific for caspasesexpressed in tumor target cellsby transient transfection,
Immunity
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Figure 4. Effect of Peptide-FMKs on Trypsin-Mediated Death of Tu-
mor Cells
Trypsin was introduced into Jurkat cells by osmotic lysis of pino-
somes, followed by a 90 min incubation at 378C without peptide-
FMKs (stippled bars) or with 10 mM ZVAD-FMK (forward slash bars),
25 mM BD-FMK (backward slash bars), or 10 mM ZFA-FMK (shaded
bars). Cell death was then assessed by trypan blue, and nuclear
morphology was determined after fixing the cells in 1% PFA and
staining with Hoechst 33342.
granule exocytosis pathway is unlikely to be due to a
failure to inhibit functional caspases. We stress that weFigure 3. Effect of Peptide-FMK Caspase Inhibitors on CTL-Medi-
ated Death of Tumor Cells have not tried to implicate particular caspase family
members in these pathways based on these results, as(A–D) Jurkat tumor cells were used as target cells for allogeneic
murine CTL (A and B) or with FasL-bearing d11S CTL (C and D) the inhibitors used do not generally distinguish between
(effector/target ratio 5 10) and the indicated concentrations of the the different caspases.
peptide FMKs. ZVAD-FMK, squares; BD-FMK, circles; ZFA-FMK, A schematic diagram of the CTL death pathways is
diamonds. Lysis was assessed by 51Cr release (A and C) and nuclear
shown in Figure 6, which is intended to highlight themorphology (B and D) by fluorescence microscopy using Hoechst
differences between the Fas (broken line) and granule33342 with targets marked with di-I-C16. Soluble anti-Fas IgG (10
exocytosis (solid line) death pathways. In both cases,mg/ml) was added to the wells in (A) and (B). The level of death
mediated by d11S CTL in the presence of soluble anti-Fas IgG is nuclear damage is shown as a separate branch that is
indicated by the asterisk in (C) and (D). linked to, but not part of, the lysis pathway. This is
(E and F) The cytotoxicity assay was identical to that in (A) and (B) based on the data presented and the demonstration
except that Fasneg L1210 leukemia cells were targets and nuclear
that enucleated and intact targets are equally sensitivedamage was measured by DNA release using L1210 cells prelabeled
to lysis by both granule exocytosis and Fas–FasL path-with [3H]thymidine. (G and H) The CTL Fas pathway was tested in
ways (Nakajima et al., 1995a), as well as previous evi-the same experiment as in (E) and (F) using a stable Fas transfectant
subline of L1210 (Rouvier et al., 1993). 51Cr release data are shown dence for CTL killing in the absence of apoptotic nuclear
as mean of triplicates with SEM. damage (Nishioka and Welsh, 1992; Sellins and Cohen,
1991). Caspases are shown as part of the Fas lytic path-
way since caspase inhibitors block the Fas-based lysis.
Although not shown in Figure 6, recent reports indicatebased on the following: the peptide-FMKs used do not
react with serine proteases, including granzyme B, un- that Fas-induced apoptotic mitochondrial damage is
also blocked by caspase inhibitors (Krippner et al., 1996;der these conditions (Shaw, 1990; Sarin et al., 1996); all
experiments included controls showing a lack of inhibi- Marchetti et al., 1996), and since this damage may be
required for other manifestations of apoptotic deathtion with the homologous cathepsin inhibitor ZFA-FMK
(Bromme et al., 1989), which lacks an aspartic acid at (Marchetti et al., 1996), it could be part of the CTL-
triggered Fas death pathway. We do not know whetherthe P1 position; except for granzyme B, caspases are
the only known aspartic acid–specific mammalian prote- the same caspases are required for nuclear damage,
mitochondrial damage, and lysis in the Fas pathway, norases. Studies on the mechanism of protease inhibition
by baculovirus p35 indicate that a critical aspartic acid– whether these are identical to the caspase(s) required
for nuclear damage by the granule exocytosis pathway.containing sequence in the protease is required for its
inhibition (Bump et al., 1995; Xue and Horvitz, 1995), This could explain why caspase activation by Fas leads
to lysis while the granule exocytosis pathway gives onlyimplying a stringent specificity for caspases. More im-
portantly, achieving the same result with two completely caspase-dependent nuclear damage. Alternatively, a
caspase-dependent lysis pathway triggered by granuledifferent types of caspase inhibitors argues that the
functional blocking achieved was attributable to cas- exocytosis could be slower than the noncaspase path-
way that preempts it. In any case, an important goal ofpase inhibition, and the failure to block lysis by the CTL
Caspase-Independent Target Lysis by CTL
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lysis by granzyme B knockout CTL argues that caspase
activation by this granule protease is not necessary for
lysis (Darmon et al., 1996; Shresta et al., 1995; Heusel
et al., 1994). Our results with peptide-FMK inhibitors are
consistent with recent studies showing that the CPP-
32-like inhibitor AcDEVD-CHO blocked target DNA re-
lease but not lysis by CTL granule exocytosis (Darmon
et al., 1996).
The scheme in Figure 6 prompts a discussion of the
common assumption that nuclear apoptotic damage is
linked to cell death. The present results argue that, for
the granule exocytosis pathway, nuclear damage re-
sulting from caspase activation is unrelated to target
cell death. While there can be little doubt that a cell that
has undergone apoptotic nuclear damage will die, this
can be preempted by more rapid lytic pathways. Thus,
the presence of apoptotic nuclear damage in target cells
does not necessarily mean that the actual cell death is
a result of molecular pathways shared with other cases
Figure 5. Effect of the Viral Caspase Inhibitor Baculovirus p35 on of apoptotic death. Target lysis by the granule exo-
CTL-Mediated Killing of L1210 Tumor Cells
cytosis pathway proceeds normally whether or not cas-
Transiently transfected L1210 cells were assayed for susceptibility
pase inhibitors shut down nuclear damage. These con-to lysis by allogeneic CTL (A) redirected for killing with a phOx-
siderations point to limitations in utilizing apoptoticanti-CD3 antibody (10 ng/ml). After 4 hr, cells were harvested and
nuclear damage as end points for death assays. Carefulassayed for residual b-galactosidase activity as described pre-
viously (Memon et al., 1995). To assay changes in nuclear morphol- functional studies with caspase inhibitors may provide
ogy (B), we stained pHook1 L1210 cells with di-I-C16 and Hoechst a more meaningful biochemical characterization of cell
33342. In (C), pHook1 L1210 target cells were prelabeled with death pathways than those based on classical apoptosis
[3H]thymidine and used as targets in the 4 hr CTL assay. In (D), p35-
criteria. Studies ongoing in our laboratory indicate thattransfected L1210-Fas cells were assayed for susceptibility to lysis
while there is a generally excellent correlation betweenby d11S CTL. After 4 hr of incubation with d11S, cells were assayed
the apoptotic death phenotype and the ability of cas-for residual b-galactosidase activity. In (A), (C), and (D), each data
point represents a mean 6 SEM of counts from three individual pase inhibitors to block death by several criteria, other
wells. exceptions to this correlation exist. In any case, the
results described in this paper point out that exclusive
focus on apoptotic nuclear damage as an indicator of
future research is to identify the nonnuclear downstream cell death is dangerous when considering functionally
targets of both caspases and granzymes that lead to cell important death pathways.
lysis. The diagram implies that the two death pathways
converge, but since there are many ways to kill a cell,
Experimental Proceduresthey may remain separate.
The scheme depicted in Figure 6 is consistent with
Mice
existing data in the literature, including granzyme C57Bl/10, C57Bl/6-MRL-lpr/lpr, and Balb/c mice between 6 and
B–mediated caspase activation in target cells (Darmon 8 weeks old were obtained from the Jackson Laboratory (Bar
Harbor, ME).et al., 1995). The lack of substantial defects in target
Figure 6. The Role of Caspases in CTL-
Induced Death Pathways
The two distinct CTL death pathways are
shown, with the granule exocytosis pathway
depicted in solid arrows and the Fas–FasL
pathway in broken lines and open arrow-
heads. Caspases are required for target cell
death by the latter pathway and for nuclear
damage via the granule exocytosis pathway,
but not for death by the granule exocytosis
pathway. In these rapid death processes, tar-
get nuclear damage does not participate in
cell death.
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